Bebig Medical Group, a Germany-based provider of high-quality radiation therapy products with a presence in China and the United States, has reportedly secured over RMB 100 million (USD 14 million) in a Series B financing round. The sole investor in this round was Cathay Capital. The funds raised are intended to expedite the global commercialization of the company’s linear accelerator and intraoperative radiotherapy technology, as well as to enhance its business operations in the field of tumor radiotherapy.
Established in 2018, the multinational firm specializes in high dose close range radiotherapy products, X-ray therapy products, and intraoperative radiotherapy products. These products have garnered marketing approvals across the EU, US, and other international markets. In the past year, Bebig Medical Group has entered into long-term global partnerships with Chinese company Shinva Medical Instrument Co., Ltd (SHA:600587) and RaySearch Laboratories, signaling a strategic expansion in the radiotherapy space.- Flcube.com
